Expression of serum survivin protein in diagnosis and prognosis of gallbladder cancer: a comparative study

Abstract

The role of survivin in gallbladder cancer (GBC) has not been evaluated. We investigated survivin protein expression in serum of patients with gallbladder diseases (cholelithiasis, n = 30; GBC, n = 39) and compared with healthy controls (n = 25). Clinicopathological parameters, diagnosis and prognosis of patients with GBC were correlated with the expression of serum survivin by enzyme-linked immunosorbent assay. Significantly higher (P < 0.0001) expression of survivin protein was observed in GBC as compared to cholelithiasis and control. Increased survivin expression was significantly associated with higher tumor stage (stage III vs. stage II; P < 0.0001) and cellular differentiation (poor and moderate vs. well differentiated; P < 0.0001) in GBC. No significant correlation was observed with any of the other clinico-pathological parameters studied. The cutoff value of survivin protein of 79 pg/ml with sensitivity of 81.16 % and specificity of 80 % differentiated the diseased group (cholelithiasis or GBC) from control group were as the cutoff value of 109 pg/ml differentiated GBC from cholelithiasis with a sensitivity of 82.05 % and specificity of 93.33 %. Though not significant, increased expression of survivin was associated with median overall survival (12 vs. 18 months; P = 0.05) in GBC patients. Our study suggests that survivin protein in serum could be both a useful diagnostic marker and an important prognostic factor for GBC.

Protein phosphatase PHLPP induces cell apoptosis and exerts anticancer activity by inhibiting Survivin phosphorylation and nuclear export in gallbladder cancer

“…GBC is primarily originated in the gallbladder and cystic duct, and accounts for the most frequent malignancies in the biliary system with high degree of malignancy. Due to its high activity of proliferation and metastasis as well as lack of specific diagnostic markers, it is hard to detect the disease at early stage, therefore, the prognosis is often poor [ 1 , 23 ]. In-depth study and screening of GBC molecular mechanisms and molecular targets, and establishment and optimization of comprehensive treatment strategies are some important aspects of improving the prognosis of patients with GBC.…”

“…In most types of human tumors, such as breast, liver, lung, colorectal, pancreatic, stomach cancers and malignant melanoma, activation of extracellular signal regulated kinase (ERK) and phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT) signaling pathways induces changes in biological behaviors, such as malignant transformation, inhibition of apoptosis, increased activity of cell proliferation and metastasis. These effects result in malignant progression of cancer and poor prognosis of patients [ 1 - 3 ]. Src and Ras oncogenes inhibit apoptosis of gallbladder carcinoma (GBC) cells by activating the epidermal growth factor receptor (EGFR) signaling pathway [ 4 ].…”

Design, Synthesis and Screening of 4,6-Diaryl Pyridine and Pyrimidine Derivatives as Potential Cytotoxic Molecules

“…53) Caspase-3 Invitrogen EIA kit Human (active) KHO1091 Invitrogen Corporation 1600 Faraday Avenue Carlsbad. 54) Cloud clone Survivin (Active) eiakit, Cloud clone, Houston, U.S.A. 55) Methodology The main principle of sandwich ELISA is the quantification of a specific protein through its containment in a sandwich of specific antibodies conjugated to the colorimetric TMB substrate, whose intensity is proportional to the protein quantity and is measured spectrophotometrically. The cell lysate is diluted 10 times, and 100 mL (50 mg protein) is added to the wells of separate micro titer plates for the ELISA kits that are precoated with primary antibodies specific to p53, Bax, Bcl-2, caspase-3, Survivin.…”

Early Diagnostic and Prognostic Value of BIRC5 in Clear Cell Renal Cell Carcinoma Based on TCGA Data

“…What's more, M. SadatKhonsari et al found that patients with suspicious renal masses cannot be precluded from being diagnosed with malignancies although, with an unsuspicious histology in CT-guided renal tumor biopsy and almost 30% of these patients, further diagnostic or therapeutic workup demonstrated a cancer diagnosis [13]. Previous several studies in other cancer types already showed that survivin can also be measured in the serum using a human surviving enzyme-linked immunosorbent assay (ELISA) [14,15,16,17,18] which makes it a noninvasive method for detecting ccRCC. In our study, the BIRC5 expression level in patients with early-stage ccRCC is signi cantly higher than in a healthy population.…”